BioceltixWAR:BCX +2.25%27 Net Current Asset Value is zł11.22 as of Mar. 2026, which is 100% below its 10-year median of 21.00. GuruFocus rates WAR:BCX with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 943 Biotechnology companies, Bioceltix ranks worse than 66.6% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Bioceltix's net current asset value per share for the quarter that ended in Mar. 2026 was zł11.22.
The historical rank and industry rank for Bioceltix's Net Current Asset Value or its related term are showing as below:
WAR:BCX'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.23 Med: 21 Max: 247.62
Current: 8.09
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of Bioceltix was 247.62. The lowest was 6.23. And the median was 21.00.
WAR:BCX's Price-to-Net-Current-Asset-Value is ranked worse than 66.6% of 943
companies
in the Biotechnology industry
Industry Median: 4.95
vs WAR:BCX: 8.09
Bioceltix (WAR:BCX) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Bioceltix Net Current Asset Value Related Terms
Bioceltix Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Bioceltix's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:BCX vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Bioceltix's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioceltix Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioceltix's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Bioceltix's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of zł11.22 mean?
Bioceltix (WAR:BCX) has a Net Current Asset Value of zł11.22 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Bioceltix and its competitors. This is 47% below median its historical median of 21.00. Over the past decade, Bioceltix's Net Current Asset Value has ranged from 6.23 to 247.62. According to the industry distribution chart, Bioceltix ranks #628 out of 943 companies in the Biotechnology industry, placing it in the top 66.6%.
Is Bioceltix's Net Current Asset Value too high?
Bioceltix's current Net Current Asset Value of zł11.22 is 47% below median its 10-year median of 21.00. Over the past 10 years, this metric has ranged from a low of 6.23 to a high of 247.62. Based on the distribution chart, Bioceltix ranks #628 out of 943 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bioceltix has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Bioceltix's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioceltix ranks #628 out of 943 companies for Net Current Asset Value. This places Bioceltix in the lower half of its industry. The industry median Net Current Asset Value is 4.95. Historically, Bioceltix's own Net Current Asset Value has ranged from 6.23 to 247.62 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.95, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Bioceltix and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioceltix's current Net Current Asset Value is zł11.22, which is 47% below median its own 10-year median of 21.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioceltix stock overvalued right now?
Bioceltix (WAR:BCX) has a current Net Current Asset Value of zł11.22. The current Net Current Asset Value is zł11.22, which is 47% below median its 10-year median of 21.00. Bioceltix's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Bioceltix (WAR:BCX), the current Net Current Asset Value is zł11.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
27GF Score
Get the complete analysis for WAR:BCX
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BCX has been successfully added to your 
